Novartis Opens Pharmaceutical Plant In Singapore, Biotech Plant to Come
Novartis (Basel, Switzerland) officially opened a new pharmaceutical manufacturing site in Tuas, Singapore on October 29, 2007, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets.
Novartis (Basel, Switzerland) officially opened a new pharmaceutical manufacturing site in Tuas, Singapore on October 29, 2007, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets.
The plant will manufacture solid dosage forms of existing Novartis pharmaceutical brands, such as Diovan, and new products, like Tekturna. It is expected to be fully operational in 2009 and will employ approximately 160 employees.
Novartis also unveiled its plan to build a large-scale biotechnology plant in Singapore to support the rapid growth of its biologics sector, which now accounts for 25 percent of the Novartis product pipeline. Novartis expects to invest approximately $700 million-its largest investment to date in manufacturing capacity-in the new, state-of-the-art cell-culture facility.
Construction on the new biotech plant is expected to start in early 2008, and it will employ more than 300 people when fully operational by the end of 2012, subject to regulatory approvals. The cell-culture plant will support both clinical and commercial production of potential new products in the area of biopharmaceutical therapies, primarily monoclonal antibodies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
